Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 08 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2017.